Greve (born 1960) is a strategic advisor at Cipriano AS. He was an M&A and capital
markets partner at Wikborg Rein & Co for 15 years until 2007 and he was a partner at the investment bank Arctic Securities ASA for a period of 3.5 years. Greve has held and holds various positions with Norwegian and international listed and unlisted companies. He holds a law degree  (cand.jur) from University of Oslo. Greve is
a Norwegian citizen and resident in Oslo, Norway.

Board member

Hammergren (born 1967) is executive vice president at the BI Norwegian Business School.She has previously been marketing director at Lilleborg, director of marketing and sales at Orkla Brands, assistant director at Schibsted and European brand manager at Unilever. Hammergren has been a director of Orkla Finans Kapitalforvaltning ASA, Adresseavisen ASA and Stenersen Forlag AS. She holds an MSc in business from the Norwegian School of Economics. She is a Norwegian citizen and resident in Oslo, Norway.

Board member

Wilhelmsen (born 1962) is co-owner and chief financial officer of WAK Family Office-Watrium. She is a director of Nordic and Europe Health Invest AS and Ultimovacs AS, and a number of the Wilhelmsen family's investment and property companies. Wilhelmsen has a degree in economics from the University of Lund, Sweden. Watrium AS today owns 12.9% of the shares in Weifa ASA. Wilhelmsen is a Norwegian citizen and resident in Oslo, Norway.

Board member

Settevik (born 1960) has extensive experience in retailing and life sciences, and is currently an independent investor and director of Made for Movement AS, Nordic Neuro Lab AS, Gentian Diagnostics AS and Holta Invest AS. He was CEO of Stokke AS in 2010-15. Before that, Settevik was CEO of Pronova BioPharma ASA after
serving as vice president pharmaceuticals and manufacturing. He has also heldseveral senior positions – VP northern Europe, VP marketing and R&D, and managing director UK/Nordic – at Tyco Healthcare EMEA, a global medical device company (acquired by Medtronic). Settevik holds a degree from Copenhagen Business School. He is a Norwegian citizen and resident in Oslo, Norway.

Board member

Jørgensen (born 1975) is currently a portfolio manager of Holta Invest AS and managing director of Holta Life Sciences AS, one of the largest shareholders in Weifa ASA. Prior to that, he had 15 years of experience as a health care analyst and portfolio manager in the life sciences sector. Jørgensen is currently a director of Gentian Technology AS and PreTect AS, both operating in the diagnostic market. He was previously a director of
Strongbridge BioPharma, a biotech company developing treatments for orphan endocrine diseases. Jørgensen holds a BSc in economics and has completed three years of medicine studies at the University of Oslo. He is a Norwegian citizen and resident in Oslo, Norway.

Board member

Børter Bekkhus (born 1978) is currently head of marketing at Weifa and joined the company in 2011. She previously worked at L’Oréal and has broad experience of marketing, PR and brand-building. Børter Bekkhus holds a Bachelor of International Marketing from the BI Norwegian Business School and a Master of Business Administration from Birmingham Business School. Børter Bekkhus is a Norwegian citizen and resident in Oslo, Norway.